C-OOYDHepaTx
stem cells, regenerative medicine, cell therapy
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OOYD
C-OOYDC-OOYDstem cells, regenerative medicine, cell therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
DNA is the blueprint of life. Since the discovery of DNA’s structure in 1953, DNA has become part of the lexicon of modern society to represent that which is most fundamental to what we are. DNA is used to build genes that contain instructions for synthesizing proteins, which in turn carry out most functions in living organisms. Consequently, the concept has garnered endless interest and generated a substantial amount of fear around the possibilities for manipulating DNA and thereby creating human tragedy. This talk will introduce the idea of genes, the fundamental functional units of DNA, and how the ability to manipulate DNA—and thus the structure of genes—is contributing to progress in the health sciences with the goal of dispelling misconceptions about genetic engineering and gene therapy. In this lecture we will look back at early human efforts to manipulate genes. Building on these early practices, we will explore how modern technologies have revolutionized genetic medicine. As
Selecting postoperative adjuvant systemic therapy... : Journal of Surgical Oncology Ovid ® Beta Ovid Logo Search Ovid Search Ovid Journal of Surgical Oncology Navbar Menu Current Issue Previous Issues Latest Articles More menu items Search Journal Search Journal Button group. Check Access Share Cite Permissions Review Article Selecting postoperative adjuvant systemic therapy for early stage breast cancer A critical assessment of commercially available gene expression assays David M. Hyams Eric Schuur Javier Angel Aristizabal Juan Enrique Bargallo Rocha Cesar Cabello Roberto Elizalde Laura Garc … 1 Copyright © 2017 John Wiley & Sons, Ltd Related Articles Customer Service Submit a Service Request Browse the help center Privacy policy Open Access Policy Legal disclaimer Terms and Copyright Manage Cookie Preferences Your California Privacy Choices Copyright © 2026 Wolters Kluwer N.V. and/or its subsidiaries or third-party licensors. All rights reserved, including those for text and data mining and artificial intelligence training. For all open access content, th … ntelligence training. For all open access content, the relevant licensing terms apply.
%PDF-1.6 %���� 335 0 obj > endobj 349 0 obj >/Filter/FlateDecode/ID[ ]/Index[335 18]/Info 334 0 R/Length 71/Prev 79003/Root 336 0 R/Size 353/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$g��� �= "dAD"�`�� �i��� 1 �H�*adic``d���� ��� endstream endobj startxref 0 %%EOF 352 0 obj >stream h�b```�r ��A��2,@ȱ��� �$�� %��``��B �,�x����;���1�j�Y�N �UN02����s30�Fi�3�N�� 20�iF �0>O) endstream endobj 336 0 obj >/Metadata 15 0 R/PageLayout/OneColumn/Pages 333 0 R/StructTreeRoot 19 0 R/Type/Catalog>> endobj 337 0 obj >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 338 0 o … 86ec092-5350-49ea-a21c-36f897546601 uuid:53a96ab4-137d-4fe1-9cf4-54d3033c112d 6 application/pdf Aiken Hackett Adobe PDF Library 19.21.79 D:20191204161741 D:20191202 D:20191202 endstream endobj 16 0 obj >stream h�266V0P���w�/�+Q0���L)�666�)�Ic0i &!� 2V?�� U? 1=��� �{� endstream endobj 17 0 obj >stream h�\�� �0 �W����K��TD��@��[;,�Eb'��V/!$����J�X.�b'�����4� !��t����Ď� �&�Bj� �3O}7߅BĹ�c��F�'�0�&�}��L�X�-�8�4ۙk8��_BE��K:��� �3١qQ�T��-v�f���O$N�:�4p��[��p?�
FDA approves new cell therapy for blindness | Benjamin McLeod posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Link … Orca Bio Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T® to Treat Hematological Malignancies FDA assigns PDUFA target action date of April 6, 2026 #CellTherapy 32 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in BCC Research 10,515 followers 8mo Edited Report this post Global pharma leaders like Pfizer , Merck Group , and Novartis dominate the brain tumor therapeutics market. But who truly has t
Student-prepared dinner yields over $16,000 - The Nugget Newspaper e-Editions Directory Photos Store About Contact Advertise Supporting Contribution Subscribe Sign In News and Opinion from Sisters, Oregon News All Sisters 2031 Holidays Education Business A & E Sports & Rec All Outdoor Recreation Outlaws Sports Rodeo Health All EveryBody's Health Fit For Sisters Fixing You Opinion All Columns Commentary Editorial Letters to the Editor Sisters Salutes Submit Letter to Editor Obits Extra All Features Inside Scoop Neighbors Nuggets From A Small Town Partners in Giving Quilt Show Spirit of Central
Japan Approves iPSC-Derived Therapies for Heart Failure and Parkinson's | Eric Schuur posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o … ort this post The firm wants to obtain feedback from the agency on its proposed application for its autologous cell therapy for ischemic heart failure. BioCardia Seeks FDA Meeting on Accelerated Approval Path for CardiAMP ebx.sh Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Booking Health GmbH 1,677 followers 1mo Report this post There’s more than one way to approach renal cell carcinoma. Dendritic cell therapy has strong potential to slow dise
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays J Surg Oncol . 2017 May;115(6):647-662. doi: 10.1002/jso.24561. Epub 2017 Feb 17. Authors David M Hyams 1 , Eric Schuur 2 , Javier Angel Aristizabal 3 , Juan Enrique Bargallo Rocha 4 , Cesar Cabello 5 , Roberto Elizalde 6 ,&
The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ( Open Payments ) Employment - Forty
The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ( Open Payments ) Patient-derived org
NIH Awards by Location and Organization - NIH Research Portfolio Online Reporting Tools (RePORT) Printer Friendly Text Size A A A U.S. Department of Health & Human Services Skip Navigation Search Home | About R e port | FAQ s | Contact Us Funding HOME > Funding > NIH Awards By Location NIH Awards by Location & Organization Explore year-by-year NIH funding by institution, state, congressional district, and more! Data frozen as of 10/16/2019. Data released on 12/20/2019 Fiscal Year : 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 … scal year, research and development contract records are integrated with frozen grant records and posted in December. Institutions may review their grant records and request updates . Show All Show All These groups will sort as a unit by their funding, number of awards, and the parent organization\'s location.')" onMouseOut="UnTip()" onfocus="Tip('Group By System/Main Campus is an in-development feature that groups together affiliated institutions such as health … 19,554 ITHACA COLLEGE ITHACA NY UNITED STATES 1 $358,669 IUOE NATIONAL TRAINING FUND WASHINGTON DC UNITED STATES 1 $1,160,939 J. CRAIG VENTER INSTITUTE, INC. LA JOLLA CA UNITED STATES 9 $4,007,054 J. DAVID GLADSTONE INSTITUTES SAN FRANCISCO CA UNITED STATES 45 $46,048,727 JACKSON LABORATORY BAR HARBOR ME UNITED STATES 112 $79,348,473 JACKSON STATE UNIVERSITY JACKSON MS UNITED STATES 6 $1,288,589 JAEB CENTER FOR HEALTH RESEARCH, INC. TAMPA FL UNITED STATES 5 $15,307,625 JAN BI … RIES, LTD. ROCHESTER NY UNITED STATES 2 $1,099,767 LIUNA TRAINING AND EDUCATION FUND POMFRET CENTER CT UNITED STATES 1 $2,736,006 LIVE INSPIRED, LLC WASHINGTON DC UNITED STATES 2 $540,294 LIVEBX, LLC CHAMPAIGN IL UNITED STATES 1 $444,916 LOHOCLA RESEARCH CORPORATION AURORA CO UNITED STATES 3 $4,801,138 LOMA LINDA UNIVERSITY LOMA LINDA CA UNITED STATES 21 $7,417,089 LOMA LINDA VETERANS ASSN RESEARCH & EDUC REDLANDS CA UNITED STATES 2 $515,680 LONG ISLAND UNIVERSITY C. W. POST … 19,554 ITHACA COLLEGE ITHACA NY UNITED STATES 1 $358,669 IUOE NATIONAL TRAINING FUND WASHINGTON DC UNITED STATES 1 $1,160,939 J. CRAIG VENTER INSTITUTE, INC. ROCKVILLE MD UNITED STATES 9 $4,007,054 J. DAVID GLADSTONE INSTITUTES SAN FRANCISCO CA UNITED STATES 45 $46,048,727 JACKSON LABORATORY BAR HARBOR ME UNITED STATES 112 $79,348,473 JACKSON STA
��ࡱ�>�� u��������pqrst�������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 9J������\pRobert B�a�=���=���W�&8X@�"��1���Arial1���Arial1���Arial1���Arial1���
PK!t6Z�z�[Content_Types].xml �(��T�N1����^ [�`�a�zT�j;� ݶ� o�lAb B\�ٶ��Lg�?\7�XAB|%zeW�u0��+�1}� ��b���o� �P�!q=�8���c�k٣>bMr����5 ?��R�?�� �����k��j4=;�ё� 2���D��&V�['��e�͚� �B��X��͖�5��?C�ǩ�8Y��_Fc�� 6v�9��.r�j( z*����ϳ1o��ȳ��?��PK!3r�ya xl/workbook.xml�VmO�6�>i�������yiQ���ѐ�!(�}Bn��y��@��}�iS ��:��ql�9�9�9ǜ|]9z�U96ȱe ^&U*�DZq;�͡��ʔ�U��� o���?�t�\�弪��fldJ�>�M��5�U�K�YT�` ^�#nj�Y�d��"�Բ ��n}����B��n-]����:S��r֨i*O��^�g�nA�u؊ v��Z�n�|%Q���� ����A�QW�a��d�O�R�7�~Ts �$�@���� ɡ�@_�F��l�\1��V�c�6@ /y�s�r�#�,UU��I0��h7�gJ�50�k�)��nt{A
Full text of "Surgery Gynecology And Obstetrics(37)" Skip to main content Keep the news in the Wayback Machine. Sign Fight for the Future's letter . Hamburger icon An icon used to represent a menu that can be toggled by interacting with this icon. Internet Archive logo A line drawing of the Internet Archive headquarters building façade. Web icon An illustration of a computer application window Wayback Machine Texts icon An illustration of an open book. Texts Video icon An illustration of two cells of a film strip. Video Audio icon An illustration of an audio speaker. Audio Software i … minal stage of earlier syphilitic Involvement such as mas found hi our ca«e’ We grant the nosubflitv that man) ol the conditions described In the bterature as s)r>hili9 of the utenis roav be the md result of eurlv s)phlhtlc Involvement But there in<c» at once the riilBculty as all experienced RmecologhU have recognized that changes m the vrvveU arc quite fretjutnl and of extreme gradation thereb) maling It Impossible m the uten that hav e undergone Mti) involullcm>. … nxmftotrapii ihoamc itut Ow mk)ont> «< iV tain* Us* riuds w coho*(Ul » th fUnd Dodn ^ (UaduU prolofit*^ dbdiaige with a fecal odor It mas found that the traa ran at a tube In diameter the rise of a Mechel t diverticulum, from the umbdicus to a pent on tbe Qeum at wtuch these dixenicula osuaUy enter it, i e about 8 ceotunetert proTtmal to the Deocecol \Tihe If the obbteraijon of tbe duct had occurred insde the abdominal wall instead of at the turlacc only a Meckel a dKcr … e only colormg matter of lie blood found 10 aolutloe in the pUsoa and tin might apply to Infontt with a«pbjTi» ^ rx]^ ite lace or where the ^ru were » «e\eTe ami frequent aj to cau*e a partbl jsphtxia rheqiK tioftha bten brought up reneated- 1} a to wbethrr Jeteru* of the newborn b rarel) hTmol)!^ hepatopinout or a innalKin of both It It comnwoly accerted ituit tbe liter prep ires Iron free liJlrrubm irooi the hxmogWiin of the erythroct lr> and other xcretei or pnsertrx th … h the opcratioo of piilro-uiterc*totnT akme This is an cxceptweial crperience I grant since m the greet majority of ca*es thb conditiofi u inoperable My hnt rtperieocc With the oiKTaUoo for ihu conditioti wa* re- ported some > ears ago rhepalwntwa»adoc tor aiul a pcrtotul (neod fh ilocnvchwas dillusel} inUliraird and preolly reduced m Mie with
WO2008021290A2 - Organ-specific proteins and methods of their use - Google Patents WO2008021290A2 - Organ-specific proteins and methods of their use - Google Patents Organ-specific proteins and methods of their use Download PDF Info Publication number WO2008021290A2 WO2008021290A2 PCT/US2007/017868 US2007017868W WO2008021290A2 WO 2008021290 A2 WO2008021290 A2 WO 2008021290A2 US 2007017868 W US2007017868 W US 2007017868W WO 2008021290 A2 WO2008021290 A2 WO 2008021290A2 Authority WO WIPO (PCT) Prior art keywords organ specific proteins specific disease detection reagents Prior art date 2006-08-0 … is and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2007/017868 Other languages French ( fr ) Other versions WO2008021290A3 ( en WO2008021290A8 ( en WO2008021290A9 ( en Inventor Leroy Hood Patricia M. Beckmann Richard Johnson Marcello Marelli Xiaojun Li Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) … n 2007-08-09 Priority to CA002660286A priority patent/CA2660286A1/en 2007-08-09 Application filed by Institute for Systems Biology, Homestead Clinical Corp filed Critical Institute for Systems Biology 2008-02-21 Publication of WO2008021290A2 publication Critical patent/WO2008021290A2/en 2008-04-17 Publication of WO2008021290A8 publication Critical patent/WO2008021290A8/en 2008-11-13 Publication of WO2008021290A3 publication Critical patent/WO2008021290A3/en 2009-02-09 Anticip … NT OF GOVERNMENT INTEREST This invention was made with government support under Grant Nos. P50 CA097186 and P01 CA085859 awarded by the National Cancer Institute. The government may have certain rights in this invention. STATEMENT REGARDING SEQUENCE LISTING The Sequence Listing associated with this application is provided on CD-ROM in lieu of a paper copy under Al § 801 (a), and is hereby incorporated by reference into the specification. Four CD-ROMs are provided containing i … ables 1A-32A, 1B-32B, 36A-45A, 36B-45B, 47A-79Aand 47B-79B associated with this application are provided on CD-ROM in lieu of a paper copy, and are hereby incorporated by reference into the specification. Three cd-roms are provided, containing identical copies of the tables, which are designed to be viewed in landscape presentation: CD-ROM no. 1
Aquillius (Published) MEMBERSHIP OFFICE SPACE LAB SPACE DIGITAL LAB SIMBIOSYX EDUCATION EVENTS VENTURES BLOG LOG IN Catalyst Capital Symposia Festival of Biologics: Investing in Women's Health Showcase Date: 4/24/2025 10:30 AM - 1:00 pm Location: San Diego Convention Center Unveil the next wave of innovation in women's health! This event is more than a showcase—it's a platform for presenting your transformative solutions to a captivated audience of investors, industry leaders, and decision-makers. Share your vision and expertise through a dynamic presentation and engage in an in … ersations to shape the future of women's health Register Attendee Investor Apply to Pitch Startup Market Register Attendee Investor Apply to Pitch Startup Market Register Get Tickets Register Get Tickets Agenda 10:40 AM - 11:40 AM 2025 Doubling Down on Women and Health Moderator: Leah Villegas, PhD, MBA Panelists: Armine Galstyan Anne Lynch Rachael Kim Allison Ramiller Anabel de la Garza 11:40 AM - 12:40 PM Startup Showcase DelNova, Inc. Examplify Therapeutics Lidavex … 0 Tax Services Free Investor Readiness Bootcamp - Top 2 Winners $4,500 for each scholarship to the Big Tree Investor Readiness bootcamp $2,500 USD in-kind services Facilitation of a CMC strategy workshop & Up to 80 additional hours of complimentary consulting support through the end of 2026 Admission to the Femovate portfolio plus $15k in award-winning digital product design. Winner will receive a slot in TechCon's Semi-finals 1 of 32) for a chance to present at Tech … ll presenters can be nominated to bypass step one of the 2026 HealthTech Impact Award - HealthTechImpactAward.com $20k in office/lab space Digital Marketing and Branding Services (worth $5,000) $10K in office/lab space $10K in office/lab space $10,000 office/lab space $25k custom UX design package from the largest femtech incubator in the US Admission to Maroon Research Institute's Global Longevity Scientific Venture Studio for 6 months and eligible investment of $125k p … ckage: 3 reports $10,000+ in Strategic Go-to-Market Engineering $4,500 for each scholarship to the Big Tree Investor Readiness bootcamp Membership to Mayo Clinic Innovation Exchange Winner will receive a slot in TechCon's Quarter-finals for a chance to present at TechCon in May with a Grand Proze of $1M Cash funding plus substantial service
The Longevity Investor Network Looks Back at 2025 Back to lifespan Home Login Return to Lifespan Homepage Donate Login News Outlet Research Biology of Aging Artificial Intelligence Decentralized Science Biomarkers Lifestyle Interventions Supplements Mindfulness Exercise Sleep Diet Financial Blockchain Investing Advocacy Policy Public Outreach LRI News Interviews Op-Ed Editorial Editor’s Pick Rejuvenation Roundup Press Releases News Outlet Research Biology of Aging Artificial Intelligence Decentralized Science Biomarkers Lifestyle Interventions Supplements Mindfulness Exercise Sleep Diet
Cell & Gene Therapy Challenges Solved with Qube Isolator Technology | Britt Steed, M.Sc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … l vector production remains a major hurdle for cell and gene therapies. In this application note from Cytiva , a scalable upstream approach is outlined using suspension adapted HEK293 cells, chemically defined media, and single use bioreactors, with successful linear scale up from 5 L to 28 L. It’s a practical look at how upstream process choices can improve yield, control costs, and support the move toward commercial manufacturing. https://lnkd.in/e8THty45 …more 4 Like Comme … dvance toward filing three BLAs in the next two years (2026-2028) including the rolling BLA of OCU400 for retinitis pigmentosa this year. Read the full press release: https://bit.ly/4qIvvya #Biotech #GeneTherapy #JPM2026 90 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in NOTRELOAD AI 218 followers 5mo Report this post REGENXBIO stock rises after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrop
Heather, Author at OTRADI --> About Facilities Startups Portal BioMentoring Events Resource Library News Sponsors About Facilities Startups Portal BioMentoring Events Resource Library News Sponsors OBI BioMembership Author: Heather OBI & OTRADI June 2026 Newsletter Posted on June 11, 2026 by Heather OBI Client Company Recent Wins AirOmatix, Inc. Received some additional funding from Portland State University’s UVDF (University Venture Development Fund). Learn more about OBI’s 30 startups by visiting our website ! OHSU President Visit Highlights Collaboration Across Oregon’s Bi … revor Nicks, PhD, grew up on a farm in Missouri and attended college on a track scholarship, studying biochemistry, business, and liberal arts. As a college junior, he helped launch a venture-backed algae engineering company, an experience that revealed both the promise and challenges of scaling biotechnology. Determined to develop technologies that could enable sustainable biology at scale, Trevor pursued a PhD at Tufts University, where he founded Caravel Bio during his fou … e opportunities for collaboration. We currently have an active $7.8 million NSF grant that I co-wrote with an Oregon State University professor, allowing us to combine complementary technologies and expertise. More recently, after an amazing year and a half at OBI, we moved into shared laboratory space with Birch Biosciences, another outstanding protein engineering company in Portland. Sharing resources has significantly extended our runway and strengthened our ability to gro … ocacy, mentorship, workforce development, and community engagement. This year’s award categories include Entrepreneur of the Year, Woman of the Year, and Legislator of the Year, and nominations are welcome for both self-nominations and peers who are driving progress in the field. Award recipients will be recognized at the Oregon Life Sciences 2026 Annual Conference taking place September 23–24 in Portland. Nominations are open through June 19. Submissions can be made HERE . S … ing to enter or grow within the field and are actively seeking opportunities to apply and expand their skills. If your team is looking for motivated emerging talent, we would be happy to connect you. Abhigyan Gargeshwari Katrina Pullman Posted in Newsletter OBI & OTRADI April 2026 Newsletter Posted on April 13, 2026 April 14, 2026 by Heather
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
Lifespan Research Institute Launches Public Longevity Group Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan … tors, while Todd White has taken on the role of Managing Director. Thalion will fund research across five key areas: embryonic rejuvenation, comparative biology, synthetic biology, tooling, and modeling. This is far more than an eclectic collection of unrelated projects – it all feeds into a single plan spanning more than a decade. Intrigued and excited, I sat down with Todd White to discuss Thalion and its role in the longevity landscape, and this role promises to be conside … they’d really like – so they run the experiments they can and hope for the next grant. Crypto, for all its easier access to capital, fell into the same small-pot, individual-project pattern. The push toward translation worried me, too: if you’re not getting government grants, you go to private equity, and private equity needs a return. VCs back small biotechs hoping for a commercializable drug, but in many cases, a whole layer of fundamental research was still missing. Gettin … you got past “this is what I do in my lab and what I need for my next paper and grant,” everyone became very open – a very different experience than a conference. We came away with about 170 questions that, if answered, would completely open up the field. João Pedro de Magalhães, from Birmingham, led turning that into a paper, published in GeroScience in November 2025 – the top 100 open questions. From the full list, we then asked what research we’d need to do, and in what or … he worst. But in one sense it was good, because it focused the people who would fund this kind of research on what really matters to them. One thing became clear: longevity has a terrible reputation right now. So, we decided we wouldn’t disclose who’s funding us unless they want to be public – the concern was almost entirely reputational. People
One cautionary tale about the business of aging research…⚠️ | Garri Zmudze LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreem … y 's Mentorship Day, three innovators became the recipient of the McMaster Seed Fund! 👏Congratulations to Block Biosciences , Tessella Biosciences Inc. , and NodeAI on receiving $245K each to advance their solutions through their commercialization journeys. Here's what they're working on: 🧬Block Biosciences is developing a first-in-class therapeutic platform designed to prevent the spread of cancer (metastasis) to the brain. 🧬Tessella Biosciences Inc. is creating high-prin … three life sciences startups have each received $245,000 from the McMaster Seed Fund to accelerate their work in cancer prevention, tissue modeling, and AI-driven healthcare. • Block Biosciences is developing proactive precision medicine to prevent metastatic brain cancer. • Tessella Biosciences Inc. is revolutionizing drug discovery with 3D-printed bioink tissue models. • NodeAI is harnessing AI to improve clinical decision-making and patient outcomes. Congratulations to the … the full story: https://lnkd.in/gRmffsSs 🔗 Learn more about the McMaster Seed Fund here: https://lnkd.in/evUFwFjW 8 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in McMaster Industry Liaison Office (MILO) 1,330 followers 8mo Report this post 🚀 Exciting news from McMaster University’s innovation ecosystem. At Mentorship Day 2025, Gianni Parise , Vice President of McMaster Research announced that three life sciences startups have each received $2 … three life sciences startups have each received $245,000 from the McMaster Seed Fund to accelerate their work in cancer prevention, tissue modeling, and AI-driven healthcare. • Block Biosciences is developing proactive precision medicine to prevent metastatic brain cancer. • Tessella Biosciences Inc. is revolutionizing drug discovery with 3D-prin
Episode 2: Eric Schuur, CEO of... - Builders of Biotech - Apple Podcasts Buscar Inicio Novedades Lo más escuchado Buscar 22 de enero de 2023 15 min Episode 2: Eric Schuur, CEO of HepaTx Builders of Biotech Reproducir Eric Schuur, co-founder and CEO of HepaTx, discusses the science behind groundbreaking stem cell therapies. We also explore the potential of such therapies to change how we fight all diseases. Sitio web del episodio Información Programa Builders of Biotech Frecuencia Dos veces a la semana Publicado 22 de enero de 2023 a las 8:38 p.m. UTC Duración 15 min Episodio 2 Clasificación Ap
Episode 2: Eric Schuur, CEO of HepaTx | Podcast Episode on RSS.com Sign up free Features Resources Pricing Podcasts Sign up free Sign In Builders of Biotech Episode 2: Eric Schuur, CEO of He... Episode 2: Eric Schuur, CEO of HepaTx Builders of Biotech by Lucas Carter E2 Jan 22, 2023 15:27 RSS feed Listen on Share About Episode notes Eric Schuur, co-founder and CEO of HepaTx, discusses the science behind groundbreaking stem cell therapies. We also explore the potential of such therapies to change how we fight all diseases. Keywords biotech stem cells liver disease Next Episode © RSS America LLC
HepaTx CEO Dr. Eric Schuur to Present at the UBS Virtual Organ Restoration and Cell Therapy Day - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HepaTx CEO Dr. Eric Schuur to Present at the UBS Virtual Organ Restoration and Cell Therapy Day October 10, 2024 | 1 min read Twitter LinkedIn Facebook Email Print San Francisco, CA — October 10, 2024 — HepaTx, a biotech company focused on advancing regenerative medicine solutions, is pleased to announce … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newsletters Podcasts Webinars Hotbeds C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HepaTx ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US Off-the-shelf cell therapies for liver disease. Using regenerative medicine technologies, HepaTx is developing new types of treatments, based on stem cells, to bring new therapies to patients with late stage liver disease, as an alternative to liver transplant. Over 30 million Americans suffer with liver disease. Of those, 200,000 people each year develop end-stage liver failure and will require an organ transplant to survive. Despite the $8. … HE SOLUTION HepaTx Awarded 2022 Impact Company of The Year Award by DotCom Magazine | READ MORE | Feb 15, 2022 Interested in learning about Investment or Career Opportunities with HepaTx? We’d love to hear from you. Please get in touch … Back To Top HepaTx Corporation Palo Alto, CA ABOUT HEPATX SCIENCE MEDIA CONTACT US
HepaTx Corporation Awarded NIH SBIR Grant to Advance Cell Therapy Monitoring Technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HepaTx Corporation Awarded NIH SBIR Grant to Advance Cell Therapy Monitoring Technology May 20, 2025 | 1 min read Twitter LinkedIn Facebook Email Print PALO ALTO, Calif., May 20, 2025 — HepaTx Corporation, a biotechnology company focused on innovative therapies and diagnostics for liver diseases, announce … nced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The Phase I grant will support the development of a proteomic assay designed to monitor transplanted cells and tissues. The project, titled “Development of a Proteomic Assay for Monitoring Transplanted Cells and Tissues” (Award Number R43DK139879), aims to addre … d improve outcomes in cell-based therapies. “We are honored to receive this NIH grant, which validates our innovative approach to tackling a significant challenge in cell therapy,” said Eric Schuur, PhD, CEO and Principal Investigator at HepaTx. “This funding will allow us to further develop our assay platform, bringing us closer to clinical applications that could improve the lives of patients with liver and other diseases.” This research is supported by the National Institu … es and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R43DK139879. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. For more information, please contact: Eric Schuur, PhD CEO, HepaTx Corporation Email: erschuur
MEDIA — HepaTx ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US HepaTx in the Media News + PR Dr. Mack C. Mitchell Joins HepaTx Clinical Advisory Board | FEATURE | Jul 10, 2023 HepaTx Welcomes Transplant Hepatologist Julio Gutierrez, MD to the Clinical Advisory Board | FEATURE | May 18, 2023 Professor Mark Thursz Joins the Hepatx Scientific Advisory Board to Advance Liver Disease Treatment | FEATURE | Apr 13, 2023 Mazen Noureddin, MD, MHSc joins HepaTx's Scientific Advisory Board | F … ry Board | FEATURE | Mar 7, 2023 HepaTx Awarded 2022 Impact Company of The Year Award by DotCom Magazine | FEATURE | Feb 15, 2022 Salah Kivlighn, HepaTx: trailblazers in the regenerative medicine technologies space | FEATURE | Feb 13, 2022 HepaTx appoints Salah Kivlighn, PhD as new CEO | FEATURE | Apr 15, 2021 ‘Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases’ | FEATURE | Mar 24, … ICLE | Dec 1, 2014 HepaTx Awarded 2022 Impact Company of The Year Award by DotCom Magazine | READ MORE | Feb 15, 2022 Interested in learning about Investment or Career Opportunities with HepaTx? We’d love to hear from you. Please get in touch … Back To Top HepaTx Corporation Palo Alto, CA ABOUT HEPATX SCIENCE MEDIA CONTACT US
MEET THE TEAM — HepaTx ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US Meet the HepaTx Team Management Team Seasoned in therapeutic technologies, with decades of company development expertise. Eric Schuur, PhD Chief Executive Officer, Co-Founder Dr. Schuur has over 25 years of experience as a scientist, manager, and consultant. He has deep scientific expertise from the bench level to the clinic at places such as UCLA, Stanford, and the Scripps Research Institute. Dr. Schuur has extensive in … y from the UCLA School of Medicine and completed an NIH-sponsored post-doctoral fellowship at the Scripps Research Institute. Dr. Schuur serves as an Adviser to the Stanford School of Medicine SPARK Program and as a Mentor in the Stanford University Office of Technology Licensing Innovation Farm Team Program. Claudia Preziosi Head of Business Development and Operations Claudia holds a master’s degree with Honors in International Business and Development fr … tential. Dr. Friedman has been awarded the EASL International Recognition Award and Distinguished Achievement Awards from both the AASLD and the American Liver Foundation. Aras Mattis, MD, PhD Scientific Advisor Dr. Mattis is an Assistant Professor in the Department of Pathology at UCSF. His training includes development of stem cell-derived human hepatocytes for modeling liver diseases. As a Liver pathologist, he has extensive experience in human li … MD, MHSc Clinical Advisor Mazen Noureddin, MD, MHSc, did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing hi … aster of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recr